Miniatura

Fitxers

PIIS016344532100356X.pdf (420.55 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-09-01

Llicència de publicació

cc by-nc-nd (c) Gudiol González, Carlota et al, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/180001

Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jinf.2021.07.014

Resum

Background: We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections and superinfections in onco-hematological patients with COVID-19. Methods: International, multicentre cohort study of cancer patients with COVID-19. All patients were included in the analysis of co-infections at diagnosis, while only patients admitted at least 48 h were included in the analysis of superinfections. Results: 684 patients were included (384 with solid tumors and 300 with hematological malignancies). Co-infections and superinfections were documented in 7.8% (54/684) and 19.1% (113/590) of patients, respectively. Lower respiratory tract infections were the most frequent infectious complications, most often caused by Streptococcus pneumoniae and Pseudomonas aeruginosa. Only seven patients developed opportunistic infections. Compared to patients without infectious complications, those with infections had worse outcomes, with high rates of acute respiratory distress syndrome, intensive care unit (ICU) admission, and case-fatality rates. Neutropenia, ICU admission and high levels of C-reactive protein (CRP) were independent risk factors for infections. Conclusions: Infectious complications in cancer patients with COVID-19 were lower than expected, affecting mainly neutropenic patients with high levels of CRP and/or ICU admission. The rate of opportunistic infections was unexpectedly low. The use of empiric antimicrobials in cancer patients with COVID-19 needs to be optimized.

Matèries

COVID-19, Infeccions oportunistes, Malalts de càncer

Matèries (anglès)

COVID-19, Opportunistic infections, Cancer patients

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GUDIOL GONZÁLEZ, Carlota, DURÀ MIRALLES, Xavier, AGUILAR COMPANY, Juan, HERNÁNDEZ JIMÉNEZ, Pilar, MARTÍNEZ CUTILLAS, Marta, FERNÁNDEZ AVILÉS, Francesc, MACHADO, Marina, VÁZQUEZ LÓPEZ, Lourdes, MARTÍN DÁVILA, Pilar, CASTRO, Nathalie de, ABDALA, Edson, SORLI, Luisa, ANDERMANN, Tessa m., MÁRQUEZ GÓMEZ, Ignacio, MORALES, H., GABILÁN, F., AYAZ, C.m., KAYAASLAN, B., AGUILAR GUISADO, Manuela, HERRERA, F., ROYO-CEBRECOS, Cristina, PEGHIN, M., GONZÁLEZ RICO, C., GOIKOETXEA, J., SALGUEIRA, C., SILVA PINTO, A., GUTIÉRREZ GUTIÉRREZ, B., CUELLAR, S., HAIDAR, G., MALUQUER, Clara, MARIN, M., PALLARÈS, Natàlia, CARRATALÀ, Jordi. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study. _Journal of Infection_. 2021. Vol. 83, núm. 3, pàgs. 306-313. [consulta: 22 de gener de 2026]. ISSN: 0163-4453. [Disponible a: https://hdl.handle.net/2445/180001]

Exportar metadades

JSON - METS

Compartir registre